Revvity RVTY Life Sciences — Segment research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept revv:SegmentResearchAndDevelopmentExpenses.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — segment research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — segment research and development expenses?
- Revvity (RVTY) reported life sciences — segment research and development expenses of $31.62M in Q1 2026.
- How has Revvity's life sciences — segment research and development expenses changed year-over-year?
- Revvity's life sciences — segment research and development expenses increased by 11.9% year-over-year, from $28.27M to $31.62M.
- What is the long-term trend for Revvity's life sciences — segment research and development expenses?
- Over 3 years (2022 to 2025), Revvity's life sciences — segment research and development expenses has grown at a 8.4% compound annual growth rate (CAGR), from $87.86M to $112.03M.
- What does life sciences — segment research and development expenses mean?
- Investment in new product development and innovation for Life Sciences.
- How do you interpret life sciences — segment research and development expenses?
- Consistent investment is vital for long-term competitiveness; sudden cuts may signal a shift in strategic focus or short-term profit preservation.
- How does life sciences — segment research and development expenses compare across companies?
- Standard 'R&D' expense metric used to benchmark innovation intensity against industry peers.